<div id="readability-page-1">New insider activity at Alnylam Pharma ( (ALNY) ) has taken place on April 7, 2026.<h3>Easter Sale - 70% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul> Alnylam Pharmaceuticals has seen insider activity as Chief Human Resources Officer Melissa McLaughlin sold 1,624 shares of the company’s stock in a transaction valued at $519,014, signaling a notable move within the firm’s executive ranks. Recent Updates on ALNY stock Alnylam updated its DemonsTTRate real‑world study of vutrisiran in transthyretin amyloidosis cardiomyopathy, underscoring execution progress and future data that could influence expectations for label expansion, adoption, and competitiveness versus other ATTR‑CM therapies. Jefferies assumed coverage and cut its price target while downgrading to a more cautious stance, citing concerns that the stock already discounts an aggressive long‑term growth path and limited competitive pressure, putting consensus forecasts at risk if markets or rivals evolve less favorably than implied. Spark’s Take on ALNY Stock According to Spark, TipRanks’ AI Analyst, ALNY is a Neutral. The score is supported primarily by the fundamental inflection to profitability and strong free cash flow, plus upbeat 2026 growth guidance and pipeline momentum from the earnings call. Offsetting this are elevated leverage and historical volatility, bearish technical trend signals, and a very high P/E that leaves little valuation cushion. To see Spark’s full report on ALNY stock, click here. More about Alnylam Pharma YTD Price Performance: -16.93% Average Trading Volume: 1,382,526 Technical Sentiment Signal: Hold Current Market Cap: $43.81B</div>

IBBQ

Alnylam Pharmaceuticals experienced notable insider activity as Chief Human Resources Officer Melissa McLaughlin sold 1,624 shares valued at $519,014. The company updated its DemonsTTRate study, indicating progress in its treatment for transthyretin amyloidosis cardiomyopathy. Jefferies downgraded ALNY's stock, citing concerns over its growth outlook. Spark's AI Analyst rates ALNY as Neutral, highlighting strong cash flow and growth guidance but noting high leverage and volatility. Year-to-date, ALNY's stock is down 16.93%, with a market cap of $43.81 billion.

Tip Ranks

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

VG Health

Direxion S&P Biotech Bull 3X

Alnylam Pharma

iShares US Pharma

ALPS Medical Breakthrough

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Direxion Daily Biotech Top 5 Bull 2X ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

Top Alnylam Executive Makes Eye-Catching Move With Company Stock